Intravenous vitamin C plus oral maintenance (500mg twice daily) for 6 months may provide value in those who receive bone marrow transplants (allogenic) for blood cancer treatment (i.e. AML, ALL, CML, MDS). It has been reported that blood levels of vitamin C are low in such patients and by correcting the blood levels may further help the body. In this study of 14 patients, overall they did better and there was sign towards lower non-relapse mortality (NMR). While the trial was small, it is nonetheless interesting and tends to mirror clinical observations we have seen throughout the years.
Feasibility of intravenous vitamin C supplementation in allogeneic hematopoietic cell transplant recipients
https://onlinelibrary.wiley.com/doi/10.1002/jha2.995
Discuss what this means for you
Research can raise useful questions. A study or individual case report does not establish that a treatment is suitable for everyone. Discuss medications, supplements and treatment changes with your care team.
Talk with our team